Nimbus Extends Seed Round, Bill Gates Invests
Nimbus Discovery, a biopharma company using computational technology to discover medicines for difficult-to-drug diseases, has added investments from Bill Gates and from Richard Friesner, the co-founder of chemical simulation software company Schrödinger. Details of the extended seed round were not released. Atlas Venture, Nimbus’ founding investor, also participated. The funds will be used to advance Nimbus’ lead programs in diffuse large B-cell lymphoma, an aggressive blood cancer, inflammatory disorders, and metabolic disease, the company said in a release.
10 March 2011•4 mins read
